Long Term Study of Solifenacin Succinate and Tamsulosin Hydrochloride Oral Controlled Absorption System (OCAS) in Males With Lower Urinary Tract Symptoms

NCT01021332 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1067

Enrollment

INDUSTRY

Sponsor class

Conditions

Lower Urinary Tract Symptoms
Benign Prostatic Hyperplasia

Interventions

DRUG: tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/6 mg)
DRUG: tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/9 mg)

Sponsor

Astellas Pharma Europe B.V.